BIO17636-T1

USE OF TRIETHYLENETETRAMINE (TETA) FOR THE THERAPEUTIC INDUCTION OF AUTOPHAGY

Autophagy is a universal anti-aging mechanism the chronic induction of which can extend the health span and lifespan of mammals. Here the inventors show that triethylenetetramine (TETA), also called trientine, a drug that is approved for the treatment of Wilson disease, can induce autophagy in mouse tissues in vivo. In particular, chronic autophagy stimulation by TETA can improve the metabolic characteristics of mice kept on a high-fat or high-sugar diet without reducing their food uptake, yet attenuating their weight gain. TETA attenuates adioposity, signs of obesity related type-2 diabetes and hepatosteatosis. TETA also mediates hepatoprotective effects against acute ethanol intoxication. Hence, TETA can be considered as a novel autophagy-inducing agent and thus can be used for the treatment of various diseases and in particular for the treatment of obesity, as well as obesity-related comorbidities.


Keywords : -
Patent Application number : -
Patent Application date : -
Multidisciplinary field : Ageing
Technology/Engineering : -
Technological Platform : -
Rare disease : -
Second indication : Yes
Inventors : -
Publications : -

Related offers


The 10 Last viewed

You haven't seen any form yet.